Literature DB >> 11837540

Neurotoxicity of MPTP.

T Fukuda1.   

Abstract

After the discovery of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), we acquired a good animal model of Parkinson's disease. The extraordinary recent growth in knowledge using MPTP parkinsonism has fostered increased understanding of Parkinson's disease. In the present paper, the discovery of MPTP and the biochemical, pathological, and clinical findings of MPTP parkinsonism are first reviewed briefly. Next, using MPTP parkinsonism, unresolved issuses such as the apoptosis of MPTP, levodopa toxicity, and neuroprotective effects of monoamine oxidase inhibitors or dopamine agonists are discussed. Finally, environmental factors such as the etiology of Parkinson's disease are examined. Some genetic factors that lead to familial Parkinson's disease have recently been reported, but most cases of Parkinson's disease are sporadic. Recent epidemiological evidence emphasizes an etiological relation of 18th and 19th century industrialization to Parkinson's disease. Man-made toxins, such as industrial chemicals and herbicides/pesticides, have been suggested to increase the risk of developing Parkinson's disease. I would like to highlight the significance of re-examination of environmental factors in the etiology of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11837540     DOI: 10.1046/j.1440-1789.2001.00402.x

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  10 in total

1.  Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of Parkinson disease.

Authors:  Héctor De Jesús-Cortés; Pin Xu; Jordan Drawbridge; Sandi Jo Estill; Paula Huntington; Stephanie Tran; Jeremiah Britt; Rachel Tesla; Lorraine Morlock; Jacinth Naidoo; Lisa M Melito; Gelin Wang; Noelle S Williams; Joseph M Ready; Steven L McKnight; Andrew A Pieper
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-01       Impact factor: 11.205

Review 2.  P7C3 and an unbiased approach to drug discovery for neurodegenerative diseases.

Authors:  Andrew A Pieper; Steven L McKnight; Joseph M Ready
Journal:  Chem Soc Rev       Date:  2014-10-07       Impact factor: 54.564

3.  Oral treatment with the NADPH oxidase antagonist apocynin mitigates clinical and pathological features of parkinsonism in the MPTP marmoset model.

Authors:  Ingrid H C H M Philippens; Jacqueline A Wubben; Bente Finsen; Bert A 't Hart
Journal:  J Neuroimmune Pharmacol       Date:  2013-03-17       Impact factor: 4.147

Review 4.  SOD2 in mitochondrial dysfunction and neurodegeneration.

Authors:  James M Flynn; Simon Melov
Journal:  Free Radic Biol Med       Date:  2013-05-29       Impact factor: 7.376

Review 5.  Epigenetic landscape of Parkinson's disease: emerging role in disease mechanisms and therapeutic modalities.

Authors:  Navneet Ammal Kaidery; Shaista Tarannum; Bobby Thomas
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

6.  Resistance to MPTP-neurotoxicity in α-synuclein knockout mice is complemented by human α-synuclein and associated with increased β-synuclein and Akt activation.

Authors:  Bobby Thomas; Allen S Mandir; Neva West; Ying Liu; Shaida A Andrabi; Wanda Stirling; Valina L Dawson; Ted M Dawson; Michael K Lee
Journal:  PLoS One       Date:  2011-01-31       Impact factor: 3.240

7.  Immunoregulation of microglial polarization: an unrecognized physiological function of α-synuclein.

Authors:  Na Li; Tessandra Stewart; Lifu Sheng; Min Shi; Eugene M Cilento; Yufeng Wu; Jau-Syong Hong; Jing Zhang
Journal:  J Neuroinflammation       Date:  2020-09-17       Impact factor: 8.322

8.  Discovery of a neuroprotective chemical, (S)-N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-6-methoxypyridin-2-amine [(-)-P7C3-S243], with improved druglike properties.

Authors:  Jacinth Naidoo; Hector De Jesus-Cortes; Paula Huntington; Sandi Estill; Lorraine K Morlock; Ruth Starwalt; Thomas J Mangano; Noelle S Williams; Andrew A Pieper; Joseph M Ready
Journal:  J Med Chem       Date:  2014-04-16       Impact factor: 7.446

9.  Concentration-Dependent Activity of Hydromethylthionine on Clinical Decline and Brain Atrophy in a Randomized Controlled Trial in Behavioral Variant Frontotemporal Dementia.

Authors:  Helen Shiells; Bjoern O Schelter; Peter Bentham; Thomas C Baddeley; Christopher M Rubino; Harish Ganesan; Jeffrey Hammel; Vesna Vuksanovic; Roger T Staff; Alison D Murray; Luc Bracoud; Damon J Wischik; Gernot Riedel; Serge Gauthier; Jianping Jia; Hans J Moebius; Jiri Hardlund; Christopher M Kipps; Karin Kook; John M D Storey; Charles R Harrington; Claude M Wischik
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

10.  The Role of Platelets in the Stimulation of Neuronal Synaptic Plasticity, Electric Activity, and Oxidative Phosphorylation: Possibilities for New Therapy of Neurodegenerative Diseases.

Authors:  Ekaterina Kopeikina; Eugene D Ponomarev
Journal:  Front Cell Neurosci       Date:  2021-07-14       Impact factor: 5.505

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.